The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments. -
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy. -
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing. -
Tivozanib Shows Superior Safety Profile Across TKIs in Metastatic Renal Cell Carcinoma
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
UROLOGIC CANCERS NEWS
Combination Therapy for Advanced Urothelial Carcinoma Shows Promise in Early Clinical Trial
Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
